Aurobindo Pharma Limited on Thursday said that its wholly owned subsidiary has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification from the US Food and Drug Administration (USFDA) for its manufacturing facility in Andhra Pradesh.
According to the company, the inspection was conducted at Unit-IV of APL Healthcare Limited in Nellore district between December 8 and December 17, 2025.
As per the USFDA, a VAI classification indicates that certain objectionable conditions or practices were observed during the inspection, but they do not warrant administrative or regulatory action by the agency.